Xu Hu

Xu Hu

Senior Reporter

Xu is passionate about understanding information and knowledge related to biopharma industry. She is bilingual in Mandarin and English. Prior to this, Xu worked as a medical writer and wrote publications based on data from clinical trials for a wide range of therapeutic areas for global pharmaceutical companies. She holds a Master degree in Medical Pharmaceutical Science from University of Groningen and a PhD degree in Biomedical Science from Vrije Universiteit Amsterdam in the Netherlands.

Latest from Xu Hu

Roche Accelerator Deepens Pool Of Potential Chinese Partners

Roche's Shanghai-based Accelerator now includes close to 20 Chinese startups across multiple areas including novel modalities and AI-based research, fitting into the Swiss major's strategy of partnering in core areas to access innovation.

Broad New China Policies Aim To Improve Market Access

China’s State Council has released a wide-ranging set of policy incentives intended to eliminate regulatory barriers and improve market access for innovative drugs.

XGene’s Non-Opioid Pain Contender Shows Pre-/Post-Op Promise

XGene's pain candidate has shown positive results in a US bunionectomy trial and the Chinese company is also eyeing chronic and cancer pain indications for its contender, which may provide a competitor to Vertex's suzetrigine.

Innovative Drugs At Center Of China’s 2024 Regulatory Efforts

The policies for China’s biopharma industry in 2024 centered around innovative small molecules, biologics and cell and gene therapies. Regulation changes for the industry in 2025 could be a continuation of that.

China’s Basic Health Insurance For Innovative Drugs Needs Reform

China is advocating reforms to health insurance, particularly the wider use of commercial schemes, for reasons to support innovative drug development.

Belief BioMed Eyes Rare Disorders With AAV-Based Gene Therapies

China's Belief BioMed presented promising new Phase III results at ASH for its AAV gene therapy for hemophilia B, although the wider China CGT space continues to be dominated by oncology.